David Kan
Vietnamese Voluntary Foundation(US)
Publications by Year
Research Areas
Genomics, phytochemicals, and oxidative stress, Glutathione Transferases and Polymorphisms, HER2/EGFR in Cancer Research, Cancer, Hypoxia, and Metabolism, Endoplasmic Reticulum Stress and Disease
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site(2009)363 cited
- → Antibody targeting of E3 ubiquitin ligases for receptor degradation(2022)237 cited
- → Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure(2006)149 cited
- → Disruption of IRE1α through its kinase domain attenuates multiple myeloma(2019)112 cited
- → Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1(2015)100 cited
- → Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft(2005)85 cited
- → IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment(2020)84 cited
- → Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels(2006)62 cited
- → Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models(2008)44 cited